SCHEMBL14424239

SCHEMBL14424239

COC(=O)c1ccc(CNc2ccnc(CI)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
CLK4 Q9HAZ1 6/20 0.47
ROCK1 Q13464 1/20 0.44
ALDH1A1 P00352 2/20 0.44
USP2 O75604 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
MAPK1 P28482 1/20 0.44
CLK1 P49759 1/20 0.44
PKM P14618 1/20 0.43
DRD2 P14416 1/20 0.43
TBXA2R P21731 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.42
DYRK1A Q13627 3/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10272801 0.85 CA1 (0.50) CA1CA2CLK4ROCK1ALDH1A1
SCHEMBL210701 0.82 CLK4 (0.50) CA1CA2CLK4ROCK1ALDH1A1
SCHEMBL14424237 0.79 CA1 (0.49) CA1CA2ALDH1A1PKMDRD2
SCHEMBL209824 0.75 CLK4 (0.74) CLK4ALDH1A1USP2CYP1A2CYP3A4
SCHEMBL210753 0.75 ALDH1A1 (0.53) CA1CA2CLK4ROCK1ALDH1A1
SCHEMBL10272800 0.75 CA1 (0.51) CA1CA2ALDH1A1PKMDRD2
SCHEMBL15761765 0.75 CXCR4 (0.66) CA1CA2ALDH1A1PKMTSHR
SCHEMBL19617458 0.74 HDAC6 (0.70) CA1CA2MAPK1DRD2TBXA2R
SCHEMBL31724971 0.74 HDAC6 (0.70) CA1CA2MAPK1DRD2TBXA2R
SCHEMBL1064735 0.74 CA1 (0.60) CA1CA2ALDH1A1PKMLOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 CA1 2297/4885CA2 1511/4885CLK4 2550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.